These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21276940)

  • 1. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
    Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
    Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of influenza A virus mRNA splicing by CLK1.
    Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
    Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.
    Eisenreich A; Bogdanov VY; Zakrzewicz A; Pries A; Antoniak S; Poller W; Schultheiss HP; Rauch U
    Circ Res; 2009 Mar; 104(5):589-99. PubMed ID: 19168442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes.
    Li P; Carter G; Romero J; Gower KM; Watson J; Patel NA; Cooper DR
    PLoS One; 2013; 8(1):e53268. PubMed ID: 23308182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells.
    Eisenreich A; Malz R; Pepke W; Ayral Y; Poller W; Schultheiss HP; Rauch U
    Circ J; 2009 Sep; 73(9):1746-52. PubMed ID: 19597299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
    Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
    Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.
    Jiang K; Patel NA; Watson JE; Apostolatos H; Kleiman E; Hanson O; Hagiwara M; Cooper DR
    Endocrinology; 2009 May; 150(5):2087-97. PubMed ID: 19116344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
    Bullock AN; Das S; Debreczeni JE; Rellos P; Fedorov O; Niesen FH; Guo K; Papagrigoriou E; Amos AL; Cho S; Turk BE; Ghosh G; Knapp S
    Structure; 2009 Mar; 17(3):352-62. PubMed ID: 19278650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
    Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
    Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
    Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
    Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
    Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
    PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
    Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
    J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.
    Liu Y; Conaway L; Rutherford Bethard J; Al-Ayoubi AM; Thompson Bradley A; Zheng H; Weed SA; Eblen ST
    Nucleic Acids Res; 2013 May; 41(9):4949-62. PubMed ID: 23519612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
    Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
    PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A.
    Yomoda J; Muraki M; Kataoka N; Hosoya T; Suzuki M; Hagiwara M; Kimura H
    Genes Cells; 2008 Mar; 13(3):233-44. PubMed ID: 18298798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
    Bowler E; Porazinski S; Uzor S; Thibault P; Durand M; Lapointe E; Rouschop KMA; Hancock J; Wilson I; Ladomery M
    BMC Cancer; 2018 Apr; 18(1):355. PubMed ID: 29606096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.